Previous close | 0.5000 |
Open | 0.5000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 22.50 |
Expiry date | 2024-07-19 |
Day's range | 0.5000 - 0.5000 |
Contract range | N/A |
Volume | |
Open interest | 102 |
FOSTER CITY, Calif. & HAYWARD, Calif., June 02, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) in third-line metastatic colorectal cancer (mCRC). These results will be presented today during an oral session
FOSTER CITY, Calif. & HAYWARD, Calif., June 01, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A1 of the Phase 2 EDGE-Gastric study. These updated data show consistent objective response rate (ORR) and provide mature progression-free survival (PFS) in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma (upper GI cancers). The
Key Insights Arcus Biosciences' Annual General Meeting to take place on 6th of June Salary of US$650.0k is part of CEO...